Anticoagulation in Mild Peripheral Vascular Disease

Evidence-Based Management of Mild PVD

• The European Society of Cardiology recommends that patients with mild Peripheral Vascular Disease (PVD) do not require anticoagulation treatment as standard therapy 1, 2
• Anticoagulation is not recommended as a standalone treatment for patients with mild PVD or intermittent claudication 2
• The 2024 ESC guidelines for peripheral arterial disease management do not recommend routine anticoagulation for patients with mild PVD 1

Recommended First-Line Therapies

• The European Heart Journal recommends antiplatelet therapy as the antithrombotic approach for patients with symptomatic PVD 1, 2
• Acetylsalicylic acid (ASA) 75-325 mg daily is recommended in all patients with symptomatic PAD to reduce the risk of major adverse cardiac events 2
• For patients with polyvascular disease and without high bleeding risk, a combination of rivaroxaban and aspirin should be considered 1

Special Considerations

• Anticoagulation is indicated for PVD patients only in specific circumstances, such as concomitant venous thromboembolism (VTE) requiring treatment 3, 4
• Anticoagulation is also indicated for atrial fibrillation with CHA₂DS₂-VASc score indicating need for anticoagulation 1
• The presence of PVD increases cardiovascular risk and is included in the CHA₂DS₂-VASc score for patients with atrial fibrillation 1

Clinical Pitfalls to Avoid

• The American College of Chest Physicians recommends not confusing management of PVD with management of venous thromboembolism, which does require anticoagulation 3, 4, 6
• Avoid unnecessary anticoagulation in mild PVD as it increases bleeding risk without proven benefit for limb outcomes 2
• PVD patients often have concomitant coronary artery disease requiring careful assessment and management 1